Lung Cancer Therapeutics Market Size to Reach USD 65.55 Billion by 2035, Driven by Precision Oncology and Biomarker-Guided Treatment

According to DataM Intelligence, the global lung cancer therapeutics market size was valued at approximately USD 28.20 billion in 2025 and is projected to reach USD 65.55 billion by 2035, expanding at a CAGR of 8.8% during 2026-2035. The market covers pharmaceutical and biological treatments used for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), including chemotherapy, immune-checkpoint inhibitors, targeted therapies, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, antiangiogenic medicines and other emerging treatment modalities.
The market is shifting from broad histology-based treatment toward more precise patient segmentation based on disease stage, histological subtype, biomarkers, treatment line and resistance patterns. Growing use of molecular testing, expansion of targeted treatments into earlier disease settings, increasing adoption of immune-checkpoint inhibitors and the development of ADCs and bispecific antibodies are reshaping treatment strategies. Commercial performance is also influenced by reimbursement, treatment duration, product eligibility, testing access and the availability of therapies for patients who progress after initial treatment.

Get More Insights from the Full Research Report: https://www.datamintelligence.com/research-report/lung-cancer-therapeutics-market?indhu

Recent Developments

• In July 2026, GSK received FDA approval for Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who had previously received at least one ROS1 tyrosine kinase inhibitor. The approval strengthens GSK's position in precision lung cancer treatment and expands options for patients with ROS1-driven disease.
• In June 2026, Nuvation Bio continued advancing taletrectinib (Ibtrozi), a targeted therapy for ROS1-positive non-small cell lung cancer, following its FDA approval in 2025. The treatment reflects the industry's increasing focus on biomarker-guided therapies designed to address specific molecular drivers of lung cancer.
• In June 2026, oncology researchers and pharmaceutical companies presented new lung cancer data at the ASCO Annual Meeting, highlighting progress in biomarker-guided treatment, targeted therapies and emerging treatment combinations. The developments demonstrate the continued shift toward more personalized treatment strategies for patients with non-small cell lung cancer.
• In 2026, Japanese oncology researchers and pharmaceutical companies continued advancing biomarker-driven lung cancer therapies, with treatment strategies increasingly tailored to specific molecular alterations. Real-world research is also evaluating treatment patterns and outcomes among Japanese patients with non-small cell lung cancer, supporting evidence-based treatment decisions.
• In 2026, Japanese lung cancer researchers continued strengthening international collaboration through the IASLC Asia Conference on Lung Cancer, scheduled to take place in Nara, Japan. The conference brings together researchers and clinicians to discuss new targeted therapies, immunotherapies, clinical trials and advances in lung cancer management.

Mergers & Acquisitions

• GSK & Nuvalent - June 2026: GSK agreed to acquire Nuvalent, strengthening its oncology portfolio with zidesamtinib and neladalkib, targeted therapies for ROS1-positive and ALK-altered non-small cell lung cancer, along with a HER2-targeted program for NSCLC.
• GSK & Nuvalent - July 2026: GSK completed the acquisition of Nuvalent, adding three lung cancer assets to its oncology portfolio and accelerating its expansion into targeted lung cancer therapies.
• AstraZeneca & Bristol Myers Squibb - August 2026: AstraZeneca and Bristol Myers Squibb held discussions over a potential combination that would have brought together two major oncology portfolios, including extensive lung cancer treatment capabilities; the discussions were subsequently terminated.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/lung-cancer-therapeutics-market?indhu

Lung Cancer Therapeutics Market Segmentation

By Disease Type
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
Lung cancer therapeutics are primarily categorized according to disease type, with non-small cell lung cancer and small cell lung cancer differing in biological characteristics, disease progression, and treatment approaches. The development of targeted and immune-based therapies is expanding treatment options across both disease types.

By Histology
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large-Cell Carcinoma
• Other Histologies
Histological classification helps determine the biological characteristics of lung tumors and supports treatment selection. Adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma represent important histological categories addressed through chemotherapy, targeted therapies, immunotherapies, and other treatment approaches.

By Stage
• Resectable Early Stage
• Unresectable Stage III
• Metastatic Disease
• Recurrent Disease
• Relapsed or Refractory Disease
Treatment strategies vary according to disease stage, tumor resectability, recurrence, and response to previous therapies. Early-stage disease may involve curative-intent approaches, while advanced, recurrent, and refractory disease often requires systemic therapies and newer targeted or immune-based treatments.

By Therapy
• Chemotherapy
• Checkpoint Inhibitors
• Targeted Small Molecules
• Monoclonal Antibodies
• Antibody-Drug Conjugates
• Bispecific Antibodies
• Other Emerging Therapies
Lung cancer treatment includes established systemic therapies as well as increasingly specialized approaches designed to target specific molecular and immune mechanisms. Growing development of checkpoint inhibitors, targeted small molecules, antibody-based therapies, antibody-drug conjugates, and bispecific antibodies is broadening therapeutic options.

By Biomarker
• EGFR
• ALK
• ROS1
• KRAS
• BRAF
• MET
• RET
• NTRK
• HER2
• PD-L1
• DLL3
• Other Targets
Biomarker testing supports the identification of molecular alterations and immune markers that can guide personalized lung cancer treatment. Expanding molecular profiling and the development of biomarker-specific therapies are increasing the importance of targets such as EGFR, ALK, KRAS, ROS1, BRAF, MET, RET, HER2, and PD-L1.

By Treatment Line
• Neoadjuvant
• Adjuvant
• Consolidation
• First Line
• Maintenance
• Second Line
• Later Line
Treatment-line segmentation reflects when a therapy is administered during the patient's treatment journey. Therapeutic strategies range from perioperative and first-line treatment to maintenance, second-line, and later-line therapies, with treatment selection influenced by disease stage, biomarkers, previous therapy, and treatment response.

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Intratumoral
• Other Routes
Route of administration varies according to the therapeutic modality, treatment setting, drug formulation, and clinical requirements. Oral and intravenous administration remain important approaches, while subcutaneous and other delivery methods are also being used for selected lung cancer therapies.

By Distribution Channel
• Hospital and Cancer-Center Pharmacies
• Buy-and-Bill
• Specialty Pharmacies
• Government Procurement
• Retail Channels
• Mail-Order Channels
Distribution channels facilitate access to lung cancer therapies across hospitals, cancer centers, specialty pharmacies, and other healthcare settings. Channel selection depends on treatment complexity, administration requirements, reimbursement structures, procurement practices, and whether therapies require specialized handling or administration.

By Region
• North America
• Europe
• Asia-Pacific
• South America
• Middle East
• Africa
Regional demand for lung cancer therapeutics is influenced by disease burden, healthcare infrastructure, diagnostic capabilities, treatment accessibility, pharmaceutical innovation, and regulatory developments. Increasing adoption of precision oncology and advanced treatment modalities is supporting market development across major global regions.

Competitive Landscape

The competitive environment is characterized by established pharmaceutical companies with strong oncology franchises competing across immune-checkpoint inhibition, targeted therapies, ADCs, bispecific antibodies and chemotherapy. Competition is increasingly shaped by biomarker-defined treatment populations, earlier-line indications, resistance management and product lifecycle expansion.

Top 5 Key Players
• Merck & Co.
• Bristol Myers Squibb
• AstraZeneca
• Roche
• AbbVie

Company profiles

• Merck & Co. - Merck maintains a major position in lung cancer through its Keytruda franchise and broad immune-oncology presence. Its portfolio benefits from use across multiple treatment settings and continued expansion of immunotherapy applications.

• Bristol Myers Squibb - Bristol Myers Squibb has a strong oncology portfolio spanning immune-checkpoint inhibition and combination treatment strategies. Its lung cancer presence is supported by established immunotherapy products and continued development across different treatment settings.

• AstraZeneca - AstraZeneca has a broad lung cancer portfolio covering targeted therapies and immuno-oncology. Its position is strengthened by products addressing biomarker-defined NSCLC populations and therapies used across earlier and advanced disease.

Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/lung-cancer-therapeutics-market?indhu

Regional Analysis
Europe represents an important regional market, although North America remains the largest region and Asia-Pacific is identified as the fastest-growing region during the forecast period. The European market is supported by established healthcare infrastructure, access to advanced oncology treatments and the increasing use of biomarker-guided treatment strategies.
The region benefits from the growing adoption of targeted therapies and immune-checkpoint inhibitors across NSCLC. Molecular profiling is becoming increasingly important as treatment decisions are segmented according to EGFR, ALK, ROS1, KRAS, MET, RET, BRAF, HER2 and other actionable alterations.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=lung-cancer-therapeutics-market?indhu

Conclusion

The lung cancer therapeutics market is undergoing a significant shift toward precision-based treatment, with patient selection increasingly influenced by disease stage, histology, biomarker status and previous treatment. NSCLC remains the largest disease opportunity, while SCLC is gaining new treatment options through immunotherapy and DLL3-directed approaches.
Targeted therapies and immune-checkpoint inhibitors continue to form important parts of the treatment landscape, while ADCs and bispecific antibodies are opening additional opportunities for patients with advanced or previously treated disease. Biomarker testing is becoming increasingly important because the commercial potential of targeted medicines depends directly on identifying eligible patients.
Regional performance will continue to differ according to disease burden, testing infrastructure, reimbursement and access to innovative therapies. North America maintains its position as the largest region, while Asia-Pacific is expected to experience the fastest growth. Europe remains an important market supported by established oncology infrastructure and increasing adoption of precision medicine.

Industry Related Reports

Peptide Drug Conjugate Market Size
The global Peptide Drug Conjugate Market reached an estimated US$ 4.53 billion in 2025 and is expected to reach US$ 25.90 billion by 2035, growing at a CAGR of 19.0% during 2026-2035. Market growth is supported by expanding peptide-based targeted delivery systems, particularly in oncology, along with the development of cytotoxic peptide conjugates, peptide-oligonucleotide conjugates, and multifunctional therapeutic platforms.
Give more insights: https://www.datamintelligence.com/research-report/peptide-drug-conjugate-market?indhu

Nanobody Drug Conjugate Market Share
The global Nanobody Drug Conjugate Market reached an estimated US$ 0.31 billion in 2025 and is expected to reach US$ 2.18 billion by 2035, growing at a CAGR of 21.5% during 2026-2035. Growth is supported by advances in nanobody engineering, targeted drug delivery, modular multispecific designs, and the potential for improved tissue penetration and more controllable therapeutic exposure.
Give more insights: https://www.datamintelligence.com/research-report/nanobody-drug-conjugate-market?indhu

Explore more Japan Reports: https://www.datamintelligence.com/jp-market-research-report?indhu

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.